Articles tagged with Molecular Imaging
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
PSMA-targeted PET/MRI performs equally well as clinical nomograms to determine risk for advanced disease in high-risk prostate cancer patients, providing valuable information for treatment planning. The study results show whole-body imaging with 68Ga-PSMA-11 PET/MRI offers a one-stop shop for staging and guiding treatment options.
A new second-generation positron emission tomography (PET) tracer has been identified for imaging tau pathology in Alzheimer's disease patients. The tracer, 18F-RO-948, showed promising results in a human evaluation study, outperforming other novel tau-specific radiopharmaceuticals.
Researchers developed a novel SPECT tracer to image c-Met expression in NSCLC, producing clearer images in less time and reducing radiation exposure. The tracer showed high specificity and rapid clearance from the body, making it potentially suitable for clinical use.
Researchers developed a hybrid nanoplatform that locates tumors using three different types of contrast simultaneously, facilitating multimodal molecular medical imaging. The platform overcomes the limitations of single image modality while maximizing their advantages.
A new preclinical study shows that PET imaging with the 18F-FAC radiotracer can image T cells in the liver, potentially reducing biopsies and improving treatment. The approach could lead to personalized treatment of patients with immune-related liver disease.
A new PET imaging radiotracer, <sup> 18 </sup> F-XTRA, was tested on adults to study the distribution of the α4β2 nicotinic acetylcholine receptor in the brain. The research found that the radiotracer rapidly entered the brain and distributed quickly, with lower binding in the hippocampus with healthy aging.
Dr. Robert Gillies, chair of Cancer Physiology and Radiology Research at Moffitt Cancer Center, receives the World Molecular Imaging Society's Gold Medal Award for his lifetime research in molecular imaging. His work focuses on understanding cancers as complex systems, leading to new cancer treatment options.
A recent study highlights the potential for misinterpretation of Prostate-Specific Membrane Antigen (PSMA) PET results, which can affect diagnostic accuracy and guide therapy. Researchers urge nuclear medicine physicians to analyze PSMA-ligand uptake in conjunction with lesion localization to avoid misdiagnosis.
Researchers used a PET tracer to identify differences in ER expression across metastases and surrounding normal tissue in breast cancer patients. The study found that approximately 50% of patients had one or more estrogen-receptor negative lesions, highlighting the heterogeneity of ER expression.
Researchers have developed a novel PET imaging method that can measure beta-cell mass, enhancing the ability to monitor and guide diabetes therapies. The new imaging method uses a radioligand to identify beta cells and has shown promising results in differentiating between healthy individuals and those with type 1 diabetes.
The Society of Nuclear Medicine and Molecular Imaging's Technologist Section recognized contributions from April Mann, Cybil Nielsen, Cheryl Rickley, and Lynne Roy for their dedication to advancing nuclear medicine technology. The awards highlight the impact of these individuals on education, advocacy, and service in the field.
The Journal of Nuclear Medicine's impact factor increased by 12% in 2017, ranking fifth among medical imaging journals. Citations to the journal rose from 24,977 to 27,101.
A novel, affibody-based pretargeted radionuclide therapy for HER2-expressing cancers demonstrated non-toxicity to the kidneys and improved survival in mice. The treatment delivered an absorbed dose to tumors that exceeded the dose to critical organs.
The Society of Nuclear Medicine and Molecular Imaging's 65th Annual Meeting showcased advancements in theranostics, quantitative nuclear imaging, and multimodality molecular imaging. Key findings include improved diagnostic accuracy and treatment options for various diseases, highlighting the potential for precision health.
A study presented at the SNMMI Annual Meeting found that early treatment of advanced prostate cancer with lutetium-177 radioligand therapy can significantly prolong life, with a median overall survival of 27 months. Patients who received first-line therapy also had the longest survival rates.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced the selection of 14 new Fellows, recognizing their excellence in volunteer service, scientific discovery, and clinical practice. The SNMMI Fellowship is one of the most prestigious formal recognitions available to long-time members.
A clinical trial found that 59% of patients with biochemical recurrence of prostate cancer had their clinical management changed by fluciclovine PET/CT imaging. The study detected disease in the prostate, pelvic lymph nodes, and less commonly, bone, guiding treatment decisions for men with recurrent prostate cancer.
Researchers found improved quality of life and reduced tumor spread in patients treated with LuPSMA therapy. PSMA PET imaging demonstrated exceptional responses, correlating with significant reductions in PSA levels.
A novel intelligent theranostic agent was designed to target tumors, with the ability to self-assemble in the tumor microenvironment and activate for therapy guided by photoacoustic imaging. The clusters showed high selectivity to the tumor microenvironment and eliminated tumor growth without subsequent recurrence.
Gambhir's work on multimodality molecular imaging has advanced nuclear medicine and healthcare. He has developed strategies to study gene and cell therapies, and his lab has more than 625 publications and over 40 patents pending.
Researchers have developed a novel approach to pretargeted radioimmunotherapy, which has shown complete responses in several solid tumor types using the beta-emitting lutetium-177 and alpha-emitting actinium-225. The new approach offers greater versatility of treatment for various solid tumors and clinical situations.
A new molecular imaging method allows early assessment of gene therapy success, potentially improving treatment for Parkinson's and Alzheimer's diseases. The PET reporter gene/probe system enables noninvasive monitoring of gene expression in all brain areas.
A new long-lasting type of radionuclide therapy has been proven effective in treating advanced neuroendocrine tumors, with the treatment lasting up to 4 times longer than previous options. The therapy, Lutathera-177 (Lu-DOTA-EB-TATE), was well-tolerated and showed promising results in a Phase I trial.
Richard L. Wahl, MD, has been recognized for his pioneering work in radioimmunotherapy, PET scans, and fusion imaging. His research has significantly contributed to understanding cancer prognosis, treatment response, and the importance of metabolic activity.
Simon Cherry has made significant contributions to biomedical imaging instrumentation and technology development, including microPET and hybrid PET/MRI systems. He is widely recognized for his work on molecular imaging and has received numerous awards for his achievements.
Researchers have developed a novel nuclear medicine probe that can detect synaptic density loss in the brain, a key biomarker for neurodegenerative diseases like Alzheimer's. The probe, using positron emission tomography (PET) imaging, has high imaging characteristics and is suitable for clinical trials and commercialization.
Researchers have demonstrated that combining targeted radionuclide therapy with immunotherapy can enhance treatment response and lead to a high cure rate in melanoma patients. This novel approach uses yttrium-86 (Y-86) NM600, which selectively targets tumors and delivers precise radiation doses.
A novel PET tracer has been developed to accurately image cardiovascular infections, which are extremely dangerous and have a high fatality rate. The tracer, called 6'-[18F]Fluoromaltotriose, is transported into bacterial cells by a membrane transport system exclusive to bacteria, allowing for specific imaging of bacterial infections.
Researchers developed a novel PSMA-targeting agent by conjugating MCG with an albumin-binding Evans blue derivative, improving tumor delivery and increasing the therapeutic effect. The agent showed significant tumor growth inhibition and complete eradication of tumors in mice, suggesting a promising strategy for cancer management.
A novel PET imaging method uses antibody fragment probes to target immune cells, detecting inflammation in the bowel and potentially guiding biopsies. The technique has wide applications in various diseases and could unlock assessment of inflammation.
Researchers developed a DOTA-conjugated NTR1 antagonist to treat and monitor pancreatic cancer, showing significant tumor growth inhibition in early studies. The novel procedure was well-tolerated by patients, with one experiencing improved symptoms and quality of life.
A new PET tracer has shown potential in predicting treatment effectiveness for depression by measuring the level of serotonin transporter protein in the brain. The study found that patients who responded to treatment had lower levels of this protein before treatment began, suggesting a biomarker for remission.
Researchers have developed a new PET imaging agent that targets NMDA receptors in nerve cells to assess treatments for various neurological diseases. The agent, C-Me-NB1, provides valuable insights into the role of NMDA receptors in brain disorders.
A novel nuclear medicine imaging agent targeting copper accumulation in tumors detects prostate cancer recurrence early in patients with biochemical relapse. The new imaging agent, copper-64 chloride (64CuCl2), has a higher detection rate than fluorine-18-choline-PET/CT in patients with low levels of PSA (<1 ng/ml).
Researchers developed a new approach that uses a single PET scan to assess PD-L1 positive tumors, enabling personalized cancer treatment. The study demonstrates the feasibility of this non-invasive method, which may help guide treatment decisions and assess treatment response.
The new TILT3D microscope produces clear 3-D images of structures and individual molecules within a cell, overcoming existing illumination techniques' limitations. Researchers can track the 3-D movement of molecules over time with high precision, enabling detailed studies of cellular structures.
The Society of Nuclear Medicine and Molecular Imaging and the American Society of Nuclear Cardiology have issued joint guidelines for the clinical quantification of myocardial blood flow using Positron Emission Tomography (PET). The guidelines provide a comprehensive framework for the measurement and interpretation of myocardial blood ...
Researchers have developed a new method to differentiate cancerous tissue from healthy tissue in prostate cancer patients using PSMA PET/CT scans. The study found that a cutoff value of SUV max = 3.15 can accurately diagnose prostate cancer with high sensitivity and specificity.
PSMA PET/CT detects prostate cancer recurrence earlier than current imaging modalities, enabling more effective salvage radiotherapy. Nearly half of patients with biochemical recurrence show positive results, with lesions often found in bone and perirectal lymph nodes.
The new total-body PET/CT scanner will advance clinical research and patient care by providing better imaging data from the whole body, reducing radiation exposure and increasing sensitivity. This technology has the potential to change cancer detection and staging methods, as well as improve diagnosis for other systemic conditions.
A new PET tracer has been developed to effectively gauge the effectiveness of promising Alzheimer's treatments in mouse models. The tracer binds to BACE1, a key enzyme involved in amyloid-β development, and accurately measures its effects on brain metabolism, neuroinflammation, and amyloid-β pathology.
A new sensor molecule allows researchers to visualize calcium concentrations in living animals without genetic modification or radiation exposure. This breakthrough enables better understanding of disease processes and has potential applications in improving medical treatments.
INRS professors François Légaré and Federico Rosei have been elected OSA Fellows for their groundbreaking work in ultrafast molecular imaging and photonic materials development. The distinction reflects their leadership, publication record, and significant impact on optics and photonics research.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/CT imaging in cancer patients. The AUC aims to improve the utilization of this technology and provide guidance for providers across specialties.
Researchers report on a new dosing regimen for actinium-225 labeled targeted alpha therapy, showing promising anti-tumor response in patients with PSMA-positive tumors. The treatment protocol balances treatment response with toxicity concerns to provide effective therapy with minimal side effects.
Theranostics combines predictive biomarkers and precise therapy to target cancer cells, minimizing side effects. The field is expected to change nuclear medicine from 'nuclear radiology' to true 'nuclear medicine,' with potential for cures.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has announced the recipients of the 2017-2019 Wagner-Torizuka Fellowship. The two-year fellowship provides extensive training and experience in nuclear medicine and molecular imaging for Japanese physicians in the early stages of their careers. This year's fellows are Sho Mo...
A new approach to optical imaging allows for fast and economical tracking of multiple molecular interactions in large areas of living tissue. The method, developed by Rensselaer Polytechnic Institute researchers, can capture interactions in mere billionths of a second and simultaneously track 16 colors of spatially linked information.
Researchers at Case Western Reserve University have developed a new multicolor MRI method that enables simultaneous detection of two different contrast agents, allowing for immediate comparisons of diseased and healthy tissue. This breakthrough has the potential to transform molecular imaging and aid disease diagnosis.
A novel PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), demonstrates potential for imaging prostate cancer. The tracer shows elevated tumor-to-background ratios and high-contrast images in human cases, suggesting its viability as a replacement for existing tracers.
The Society of Nuclear Medicine and Molecular Imaging has published appropriate use criteria (AUC) for hepatobiliary scintigraphy in abdominal pain. The new guidelines aim to ensure cost-effective and appropriate utilization of advanced diagnostic imaging services, helping referring physicians make informed decisions.
The Society of Nuclear Medicine and Molecular Imaging recognized Robert E. Henkin, MD, for his 30-year dedication to the field of nuclear medicine, while John M. Hoffman, MD, was honored for his expertise in molecular imaging research and leadership roles in the SNMMI Clinical Trials Network.
Researchers developed a novel imaging tracer that allows for early assessment of abdominal aortic aneurysm (AAA) risk. The study shows high sensitivity and specificity in detecting vessel wall biology, suggesting a promising tool for AAA risk stratification.
The Society of Nuclear Medicine and Molecular Imaging's Technologist Section recognized the work of several award-winning nuclear medicine technologists, including Amanda Abbott, Dusty M. York, Cindi Luckett-Gilbert, Margaret M. Doonan, and Robert A. Pagnanelli, for their contributions to education and service in the field.
Monash University researchers have identified a key part of the process by which a common clinical antibiotic is formed, paving the way for novel compounds to tackle bacterial resistance. By understanding this process, scientists can manipulate it to create modified compounds that could help combat superbugs.
A Phase II study found that increasing radiotherapy doses to hypoxic non-small cell lung cancer (NSCLC) lesions, identified by PET/CT scans, did not improve patient outcomes. The study suggests that smaller volumes of tumors with hypoxia may be more effectively targeted for radiotherapy.
Researchers have developed a novel PET tracer that can detect small blood clots in veins and arteries, providing valuable information for diagnosis and treatment. The tracer binds to GPIIb/IIIa receptors, targeting the critical molecular components involved in platelet clumping.
The Journal of Nuclear Medicine ranked 5th in impact factor among medical imaging journals, increasing to 6.646 in 2016, with a 5-year impact factor of 6.459. Citations increased to 24,977, and article influence score is 1.84.
Researchers demonstrate preclinically that dual-labeled PSMA-inhibitors improve preoperative staging and intra-operative guidance for metastatic prostate cancer patients. This combined approach results in more accurate detection of PSMA-positive tumor lesions, enhancing patient outcomes.
A new imaging test, Ga-68 PSMA PET/CT, has been shown to detect cancer that conventional imaging missed, changing treatment plans for 51% of patients. The test also improved management for patients with recurrent disease, with 69% receiving radiation therapy and 64% undergoing surgery.